Contraception is the exclusion category that makes Catholic investing awkward at dinner parties. Explaining why you don't own Johnson & Johnson is one thing when the topic is abortion. It's another thing entirely when you have to explain why birth control pills disqualify a company that also makes Band-Aids, Tylenol, and cancer treatments.

But the USCCB Socially Responsible Investment Guidelines are clear on this: companies whose business includes meaningful contraceptive manufacturing get excluded. The moral theology is consistent, it just requires actually understanding the Church's teaching, which most Catholics don't.

The theological foundation

You can't understand Catholic contraception screening without understanding Humanae Vitae. Paul VI issued the encyclical in July 1968, and it's probably the most controversial papal document of the 20th century in terms of lay reception.

Paragraph 11 of Humanae Vitae contains the key teaching: "Each and every marriage act must remain open to the transmission of life." The Church's argument is that sexuality has two inseparable purposes, unitive (joining spouses) and procreative (open to children). Contraception separates these purposes and therefore violates the natural moral law.

This teaching was reaffirmed by John Paul II in Familiaris Consortio (1981) and Veritatis Splendor (1993), and it's repeated in the Catechism paragraph 2370: "Periodic continence, that is, the methods of birth regulation based on self-observation and the use of infertile periods, is in conformity with the objective criteria of morality. These methods respect the bodies of the spouses, encourage tenderness between them, and favor the education of an authentic freedom. In contrast, every action which, whether in anticipation of the conjugal act, or in its accomplishment, or in the development of its natural consequences, proposes, whether as an end or as a means, to render procreation impossible is intrinsically evil."

The phrase "intrinsically evil" is significant. In Catholic moral theology, intrinsically evil acts are wrong regardless of circumstances or intentions. You can't find a context that makes contraception permissible. That's why the USCCB guidelines treat it as a categorical exclusion.

Which companies get flagged

Johnson & Johnson (JNJ) is the biggest name on the list. Through its Janssen Pharmaceutical subsidiary, J&J produces several contraceptive products including Ortho Tri-Cyclen and Ortho Evra. The company's total pharmaceutical revenue is massive, and contraceptives are a small percentage, but the connection is direct enough to trigger Catholic exclusion screens.

Bayer AG (BAYRY) is another major player. Bayer produces Yaz, Yasmin, and Mirena, three of the most prescribed contraceptive products globally. The company also produces some medications with potential abortifacient effects, which compounds the exclusion.

Pfizer (PFE) has contraceptive products through its acquisition history, though it's less central to their business than at J&J or Bayer.

Teva Pharmaceutical (TEVA) produces generic contraceptives, which means it's a major supplier even though the brand recognition is lower.

Merck (MRK) has NuvaRing and other contraceptive products in its portfolio.

Allergan (part of AbbVie/ABBV now) historically had contraceptive products, and that ownership passed through to AbbVie after the acquisition.

These are all major Dow Jones or S&P 500 components. Excluding them creates a significant hole in healthcare allocation for Catholic portfolios.

The revenue threshold question

Unlike abortion (zero tolerance), contraception exclusions in most Catholic fund methodologies allow for revenue thresholds. The standard is typically 5 percent of total revenue. If more than 5 percent of a company's revenue comes from contraceptive products, it gets excluded. Below that, there's prudential room.

The reasoning is based on Catholic moral theology on material cooperation with evil. The Catechism paragraph 1868 distinguishes between formal cooperation (intending the evil act, always forbidden) and material cooperation (performing acts that facilitate evil without intending it, sometimes permitted). For material cooperation, the permissibility depends on proximity (how close you are to the act) and proportionate reason (whether there's sufficient justification).

Owning a tiny fraction of a huge company whose contraceptive revenue is small and incidental is remote material cooperation, potentially permissible. Owning a company whose business model centers on contraception is proximate material cooperation, not permissible.

The 5 percent threshold is a practical compromise that most Catholic fund managers find workable. It's not infallible doctrine; it's prudential judgment about where the line of remoteness lies.

Why this isn't just "Catholic weirdness"

A common reaction from non-Catholic investors is that contraception screening is idiosyncratic Catholic concern that shouldn't affect mainstream thinking about investing. The USCCB guidelines reject this framing.

The argument the bishops make is that sexuality, fertility, and human dignity are foundational concerns that apply to every human being, not just Catholics. Humanae Vitae paragraph 17 predicted specific social consequences of widespread contraception: increased infidelity, declining moral standards, men losing respect for women, and governments using contraception as a tool of population control. You can debate how accurate those predictions were, but the underlying concern is about human dignity, not sectarian rules.

Caritas in Veritate (Benedict XVI, 2009) paragraph 15 connects development economics to respect for life: "When a society moves toward the denial or suppression of life, it ends up no longer finding the necessary motivation and energy to strive for man's true good." That's a claim about the relationship between moral culture and economic flourishing that applies beyond Catholic circles.

So while the contraception exclusion is distinctly Catholic, the moral reasoning behind it is universal. The USCCB guidelines treat it that way.

Portfolio implications

Excluding contraception manufacturers has real consequences for Catholic portfolios. Healthcare is normally 13 to 14 percent of the S&P 500, and the pharmaceutical subsector within healthcare is dominated by the companies that get flagged.

Losing JNJ alone is significant. It's one of only two companies with an AAA credit rating, it's a dividend aristocrat with over 60 consecutive years of dividend increases, and its beta is around 0.6, making it a classic defensive holding. Catholic portfolios have to find substitutes.

What works as a replacement?

UnitedHealth Group (UNH) has different moral issues (healthcare insurance practices have their own concerns), but it doesn't trigger contraception screens directly.

Thermo Fisher Scientific (TMO) provides healthcare exposure through lab equipment and diagnostics without the contraceptive issue.

Intuitive Surgical (ISRG) focuses on robotic surgery systems, which don't trigger the exclusions.

Stryker (SYK) makes orthopedic and medical devices without contraceptive products.

Edwards Lifesciences (EW) focuses on heart valves and surgical monitoring.

IDEXX Laboratories (IDXX) provides veterinary diagnostics, which is a clean healthcare exposure.

Catholic mutual funds typically build a healthcare allocation from names like these rather than the big pharma giants. The tracking error versus broad healthcare indexes is real but manageable.

The Ave Maria approach

Ave Maria Mutual Funds (AVMNX) is the largest Catholic fund family by assets, and they've publicly discussed their contraception screening methodology. Their approach is relatively strict: they exclude companies with any meaningful contraceptive manufacturing, not just those over the 5 percent threshold.

This leads to portfolio differences versus other Catholic funds. Ave Maria excludes JNJ categorically. Knights of Columbus Asset Management uses more engagement-oriented approaches. Catholic Responsible Investments funds sit somewhere in between.

All three are faithful Catholic interpretations. The differences reflect prudential judgments about where the line falls, not theological disagreements about whether contraception is wrong.

What about birth control for non-contraceptive use

Some medications that Catholic teaching opposes as contraception have other medical uses. Oral contraceptives are prescribed for endometriosis, polycystic ovary syndrome, acne, and other conditions. The moral analysis for using such medications is complex and context-dependent, and the Church's teaching in Humanae Vitae is specifically about contraceptive intent, not the chemical itself.

Does this affect investment screening? Catholic fund managers generally say no, because the question isn't about individual medical ethics but about corporate business models. Companies manufacture and market these products primarily as contraceptives, even if some uses are legitimate. The revenue they generate comes overwhelmingly from contraceptive use. So the exclusion stands.

The engagement alternative

Some Catholic investors argue that engagement rather than divestment is the right approach for contraception-connected companies. The logic: by owning stock, you have a voice. You can file shareholder resolutions, vote proxies, and push for changes in product lines or corporate behavior.

This approach has appeal but limited practical effect on contraception specifically. You're not going to persuade J&J to stop making Ortho Tri-Cyclen. It's a profitable product line with significant market share. Shareholder engagement works better for adjacent issues like drug pricing, access to medicines in developing countries, and clinical trial ethics.

For contraception itself, divestment is the practical path. The USCCB guidelines allow either approach in principle, but the bishops acknowledge that some product lines are unlikely to be changed through engagement.

The bigger picture

Catholic teaching on contraception is one of the most counter-cultural positions the Church holds. Most Catholics in the United States don't agree with it or don't follow it. Polls consistently show majority Catholic approval of contraception use.

That reality doesn't change the moral theology or the investment implications. The USCCB guidelines reflect the Church's official teaching, and Catholic fund managers who screen out contraception manufacturers are being consistent with that teaching, even if it puts them at odds with popular opinion.

The Catechism paragraph 1706 says that moral law depends on "truths concerning God and man, and their relationships." For Catholic investors who take Humanae Vitae seriously, screening out contraception manufacturers is one way of affirming those truths in a concrete, costly way. Your portfolio stops being morally neutral and becomes a statement.

It's an uncomfortable statement for a lot of people. But the USCCB guidelines are clear about why it has to be made. You don't get to selectively apply Catholic social teaching based on what's convenient. Either the moral framework applies or it doesn't, and the bishops think it does.

Contraception Manufacturers: How USCCB Treats Pharma Giants